Alkem Labs to Acquire Adroit Biomed and Bombay Ortho for INR 287 Cr

The company will acquire a 100% stake in Adroit Biomed Ltd. for INR 140 crore and Bombay Ortho Industries Pvt Ltd. for INR 147 crore, strengthening its position in the Indian healthcare market.

Alkem Laboratories has announced two acquisitions to expand its presence in the dermatology and medical devices sectors. 

The company will acquire a 100% stake in Adroit Biomed Ltd. for INR 40 crore and Bombay Ortho Industries Pvt Ltd. for INR 147 crore, strengthening its position in the Indian healthcare market.

Acquisition in Dermatology: Strengthening Skincare Portfolio

Alkem’s acquisition of Adroit Biomed, a pharmaceutical company focused on skincare, will enhance its dermatology and cosmetology offerings. Adroit Biomed’s portfolio includes key brands such as Glutone, SkinFay, Racine, and FortiSil. The company reported a revenue of INR 53.55 crore in the financial year ending March 2024.

BN Singh, Chairman of Alkem, stated, “The acquisition of Adroit will enable Alkem to diversify its portfolio, enhance market penetration, and strengthen its presence in the growing segments of dermatology and cosmetology.”

Alkem expects to complete this acquisition by April 1, 2025, subject to regulatory approvals and other closing conditions.

Medical Devices Expansion: Investment in Orthopaedic Implants

Alkem’s subsidiary, Alkem MedTech, has signed a binding offer to acquire Bombay Ortho Industries, a manufacturer of orthopedic implants. This move aligns with the company’s strategy to expand its presence in the medical technology sector.

Sandeep Singh, Managing Director of Alkem, stated, “Medtech is a fast-growing space in India, and the patient’s need for quality products is high. We aim to meet the growing demand for implants in India through our acquisitions in the medical devices segment.”

The acquisition of Bombay Ortho is expected to be completed by June 30, 2025, following necessary approvals.